Literature DB >> 11920576

Regulation of activation-induced receptor activator of NF-kappaB ligand (RANKL) expression in T cells.

Ruoxiang Wang1, Liying Zhang, Xiaoren Zhang, Jose Moreno, Christina Celluzzi, Mehrdad Tondravi, Yufang Shi.   

Abstract

Receptor activator of NF-kappaB ligand (RANKL) is a type II membrane protein of the TNF family and plays a critical role in the regulation of osteoclastogenesis. RANKL expressed on osteoblastic stromal cells has been shown to support osteoclast differentiation originated from hematopoietic precursors. Interestingly, RANKL is also expressed on cells of the immune system including T cells and dendritic cells. We have shown that anti-CD3 could induce RANKL expression in T cell hybridoma A1.1 cells and splenic T cells. RANKL expressed on T cells could effectively induce osteoclast formation from the whole population of murine splenocytes. Furthermore, we have found that the induction of RANKL expression is solely dependent on TCR activation-induced Ca2+ mobilization since its expression can be blocked by cyclosporine A and TMB-8, a Ca2+ mobilization inhibitor. Additionally, treatment of A1.1 cells with ionomycin alone also strongly induces RANKL expression, while phorbol myristate acetate by itself does not. Moreover, although inhibition of c-myc has significant effects on anti-CD3-induced Fas ligand (FasL) expression, we have found that the anti-CD3-induced RANKL expression is independent of c-myc. Surprisingly, in contrast to its inhibitory effect on FasL expression, TGF-beta dramatically increased the expression of anti-CD3-induced RANKL expression. In addition to its potential role in immune responses, RANKL expressed on activated T lymphocytes may provide a mechanism for the communication between the immune and skeletal systems during immune responses and disease states such as rheumatoid arthritis.

Entities:  

Keywords:  Non-programmatic

Mesh:

Substances:

Year:  2002        PMID: 11920576     DOI: 10.1002/1521-4141(200204)32:4<1090::AID-IMMU1090>3.0.CO;2-P

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  25 in total

1.  Cervical Pannus Without Rheumatoid Arthritis or Trauma.

Authors:  Carl Hoegerl; Rafail Beshai
Journal:  Fed Pract       Date:  2020-04

Review 2.  Osteoimmunology: interactions of the bone and immune system.

Authors:  Joseph Lorenzo; Mark Horowitz; Yongwon Choi
Journal:  Endocr Rev       Date:  2008-05-01       Impact factor: 19.871

3.  Mouse Rankl expression is regulated in T cells by c-Fos through a cluster of distal regulatory enhancers designated the T cell control region.

Authors:  Kathleen A Bishop; Heidi M Coy; Robert D Nerenz; Mark B Meyer; J Wesley Pike
Journal:  J Biol Chem       Date:  2011-04-12       Impact factor: 5.157

4.  Dual Functional MicroRNA-186-5p Targets both FGF2 and RelA to Suppress Tumorigenesis of Glioblastoma Multiforme.

Authors:  Fachen Wang; Hui Jiang; Shanjun Wang; Bing Chen
Journal:  Cell Mol Neurobiol       Date:  2017-02-17       Impact factor: 5.046

5.  Upregulation of receptor activator of nuclear factor-kappaB ligand expression in the thymic subcapsular, paraseptal, perivascular, and medullary epithelial cells during thymus regeneration.

Authors:  Hee-Woo Lee; Bong-Seon Kim; Hyung-Jin Kim; Choong-Won Lee; Hyun-Jung Yoo; Jae-Bong Kim; Sik Yoon
Journal:  Histochem Cell Biol       Date:  2005-04-21       Impact factor: 4.304

6.  Activated T lymphocytes suppress osteoclastogenesis by diverting early monocyte/macrophage progenitor lineage commitment towards dendritic cell differentiation through down-regulation of receptor activator of nuclear factor-kappaB and c-Fos.

Authors:  D Grcević; I K Lukić; N Kovacić; S Ivcević; V Katavić; A Marusić
Journal:  Clin Exp Immunol       Date:  2006-10       Impact factor: 4.330

7.  Novel murine mammary epithelial cell lines that form osteolytic bone metastases: effect of strain background on tumor homing.

Authors:  Yanping Chen; Susan R Rittling
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

8.  RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer.

Authors:  Elizabeth Ahern; Heidi Harjunpää; Jake S O'Donnell; Stacey Allen; William C Dougall; Michele W L Teng; Mark J Smyth
Journal:  Oncoimmunology       Date:  2018-02-14       Impact factor: 8.110

9.  DACH1 negatively regulates the human RANK ligand gene expression in stromal/preosteoblast cells.

Authors:  Kumaran Sundaram; Santhosh K Mani; Kazuyuki Kitatani; Kongming Wu; Richard G Pestell; Sakamuri V Reddy
Journal:  J Cell Biochem       Date:  2008-04-15       Impact factor: 4.429

10.  FGF-2 stimulation of RANK ligand expression in Paget's disease of bone.

Authors:  Kumaran Sundaram; Joseph Senn; Sambandam Yuvaraj; D Sudhaker Rao; Sakamuri V Reddy
Journal:  Mol Endocrinol       Date:  2009-06-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.